Insights

Three experts discuss HIV management with PrEP therapies, highlighting the major obstacles that can impact these patients and what can be done to improve their quality of life.

Three experts discuss the use of biosimilar and interchangeable biosimilars, exploring how the treatment landscape will change in the upcoming years.

A panel of expert medical professionals navigate the evolving landscape in biomarker testing for treating patients with metastatic colorectal cancer.

Three experts discuss advanced non-small cell lung cancer and what it means to have a treat a KRAS G12C mutation.

Two experts, one provider and one payer, shed light on their experiences with prescription digital therapeutics within the behavioral care landscape.

Two experts discuss the role immunomodulatory drugs (IMiDs) play in the current treatment landscape for relapsed/refractory multiple myeloma and how they can be used effectively.

Ian Riddock, MD, and Eliot Brinton, MD, discuss effective use of lipid lowering therapies in patients with atherosclerotic cardiovascular disease (ASCVD).

Shared insight on the role cardiovascular disease management plays in the prostate cancer treatment paradigm.

Ryan Haumschild, PharmD, MS, MBA, and Kathy Oubre, MS, discuss the use of biosimilars at their organizations and what payers should be thinking about when considering biosimilar transitions.

X. Long Zheng, MD, PhD, gives an overview of acquired thrombotic thrombocytopenic purpura and the treatment considerations for the disease.